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In previous in vitro studies, we showed that Transient Receptor
Potential Canonical 3 (TRPC3), a calcium-permeable, nonselective
cation channel endowed with high constitutive function, is an
obligatory component of the inflammatory signaling that controls
expression of the vascular cell adhesion molecule-1 (VCAM-1) and
monocyte adhesion to coronary artery endothelial cells. Also, TRPC3
expression in these cells was found to be up-regulated by proathero-
genic factors, which enhanced inflammation and VCAM-1 expres-
sion. However, it remained to be determined whether these in vitro
findings were of relevance to atherosclerotic lesion development in
vivo. To answer this important question in the present work, we
generated mice with endothelial-specific overexpression of human
TRPC3 in an Apoe knockout background (TgEST3ApoeKO) and
examined lesions in the aortic sinus following 10 and 16 wk on a
high-fat diet. No significant differences were found in size or
complexity of early stage lesions (10 wk). However, advanced
plaques (16 wk) from TgEST3ApoeKO mice exhibited a significant
increase in size and macrophage content compared with non-
transgenic littermate controls. Remarkably, this change was corre-
lated with increased VCAM-1 and phospho-IkBα immunoreactivity
along the endothelial lining of lesions from transgenic animals com-
pared with controls. These findings validate the in vivo relevance of
previous in vitro findings and represent, to our knowledge, the first
in vivo evidence for a proatherogenic role of endothelial TRPC3.
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Members of the Transient Receptor Potential Canonical(TRPC) family of calcium-permeable, nonselective cation
channels are involved in numerous molecular and cellular events
associated to cardiovascular physiology and disease (1, 2). A great
deal of experimental evidence documents the participation of
TRPC channels in signaling mechanisms linked to the pathogenesis
of essential hypertension, cardiac hypertrophy, intima hyperplasia
and endothelial dysfunction, among others (1, 2). TRPCs belong
to the TRP superfamily of channel forming proteins and are
grouped as follows: TRPC1, TRPC2, TRPC3/6/7, and TRPC4/5
(3, 4). Regardless of the expression system TRPCs form nonvoltage
gated, calcium-permeable nonselective cation channels activated
downstream of receptor-stimulated phospholipases (3, 4). How-
ever, among all TRPCs, TRPC3 also forms channels endowed with
significant constitutive function that is manifest both in over-
expression and native expression conditions (4–6). Despite their
recognized roles in cardiovascular disease, the potential functions
of TRPCs in atherosclerosis, the major cause of death due to
coronary artery disease in western societies, has remained largely
unexplored (discussed by us in refs. 2 and 7). Atherosclerosis is a
chronic disease of the arterial wall with a clear maladaptive in-
flammatory component, and implies a complex interplay between
mechanisms intrinsic to the endothelium and genetic and envi-
ronmental factors (8). Endothelial inflammatory signaling, mono-
cyte recruitment, and the balance between survival and apoptosis
of lesional macrophages, are all fundamental in initiation and
progression of atherosclerotic lesions as well as in determining the
fate of the plaque at advanced stages (9, 10). A paramount piece
of experimental evidence supporting a role of TRPC3 in athero-
genesis was provided by our recent findings in a mouse model of
atherosclerosis demonstrating that TRPC3 contributes to mecha-
nisms underlying necrotic core growth in advanced atherosclerotic
plaques of Apoe knockout (ApoeKO) mice by influencing the rate
of apoptosis of lesional macrophages (11). However, the expression
of TRPC3 is ubiquitous and macrophages are not the sole athero-
relevant cells where this channel is present. In previous in vitro
studies using human coronary artery endothelial cells, we showed
that native TRPC3 forms calcium-permeable channels that medi-
ate both constitutive and regulated calcium influx (12). In these
cells, TRPC3 expression and its constitutive function are obligatory
components of the proinflammatory, nuclear factor kappa B alpha
(NFkBα)-dependent signaling that drives expression of the vascular
cell adhesion molecule-1 (VCAM-1), one of the key adhesion
proteins that in vivo mediate monocyte recruitment into the arterial
wall (13). In addition, we also reported that lesions in the aortic root
of atherosclerotic ApoeKO mice exhibited robust TRPC3 expres-
sion compared with aortic cross-sections from nonatherosclerotic
animals (13). Nevertheless, because of the several factors that un-
derlie lesion development in vivo a definitive relationship between
increased expression of TRPC3 and atherogenesis could not be
established. It was thus obvious that generation of mouse models of
atherosclerosis in which TRPC3 expression could be manipulated
was required (i.e., conditional transgenic or knockout animals for
TRPC3) to properly appreciate the contribution of endothelial
TRPC3 to lesion development in vivo.
To address this contribution, in the present work we gener-
ated mice with endothelial-specific overexpression of human
TRPC3 in an ApoeKO background (TgEST3ApoeKO) and
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examined lesions in the aortic sinus following 10 and 16 wk on a
high-fat diet to accelerate development of atherosclerosis.
Whereas no significant differences were found in the character-
istics of early stage atherosclerotic lesions (10 wk), advanced
plaques (16 wk) from TgEST3ApoeKO mice were larger and with
higher macrophage content than in control animals. Remarkably,
this correlated with increased density of VCAM-1 immunoreactive
areas and NFkB activation along the endothelial lining of lesions
from transgenic animals compared with those in nontransgenic
littermates. These findings validate the in vivo relevance of our
previous in vitro findings and represent, to our knowledge, the first
in vivo evidence for a proatherogenic role of endothelial TRPC3.
Results
In this study, we examined the impact of endothelial-specific
overexpression of human TRPC3 on the characteristics of early
and advanced atherosclerotic lesions in Apoe knockout (ApoeKO)
mice. As described in Methods, endothelial-specific overexpression
of the human TRPC3 gene (hTRPC3) was achieved by having
hTRPC3 cDNA under control of the human Flt-1 promoter that
confers endothelial-specific gene expression (14). Expression of
hTRPC3 at the protein level was confirmed by immunoblot of
proteins from lung lysates from TgEST3ApoeKO mice with an
anti-HA antibody (12CA5), which detects expression of the HA-
tagged hTRPC3 in TgEST3ApoeKO but not in nontransgenic
littermates (Fig. 1B). Lungs have a high content of endothelial
cells, facilitating immunoblot detection of HA-tagged TRPC3 of
endothelial origin. Contrarily to what is observed with other en-
dothelial promoters (e.g., Tie2, Ve-cadherin), there was no ex-
pression of TRPC3-HA in bone marrow-derived macrophages
from TgEST3ApoEKO mice, which is of importance as we re-
cently showed that macrophage TRPC3 influences the charac-
teristics of early and advanced atherosclerotic lesions of ApoeKO
mice by virtue of its role in mechanisms associated to macrophage
apoptosis (11, 15). Immunohistochemistry for HA epitope in
aortic root sections from the transgenic mice confirmed endo-
thelial localization of TRPC3-HA (Fig. 1C).
At 8 wk of age, female TgEST3ApoeKO mice or their non-
transgenic littermates were placed on a Western-type high-fat
diet (HFD; TD.88137, Harlan Laboratories) for 10 or 16 wk to
allow for development, respectively, of early and advanced ath-
erosclerotic lesions. At sacrifice, body weight, plasma choles-
terol, and triglycerides were determined. As shown in Table 1,
there were not significant differences in these parameters be-
tween transgenic and nontransgenic mice after either diet period.
To examine the impact of endothelial-specific overexpression of
hTRPC3 on the characteristics of atherosclerotic lesions we per-
formed histological analysis of heart sections at the level of the
aortic sinus, as we described in detail in refs. 11 and 13. Based on
morphometric evaluation of hematoxilin-eosin–stained sections,
after 10 wk on HFD, lesions in transgenic mice were somewhat
larger than in control mice, although not reaching statistical sig-
















Fig. 1. Transgene expression. (A) PCR performed on gDNA derived from tail biopsies of TgEST3ApoeKO mice (“TgEST3”) using the genotyping primers
described in Methods which amplify the expected amplicon of 334 bp spanning the last 92 bp of Trpc3-HA plus 212 bp of the polyA tail. Primers and PCR
conditions for Apoe were as recommended by Jackson Labs (Apoe+/+ and Apoe+/− are included as controls). (B) Lung lysates from endothelial-specific TRPC3-
HA transgenic mice (“TgEST3”) or their nontransgenic littermates (“Non-Tg”) were subjected to immunoprecipitation using anti-HA antibody (12CA5) and
immunoprecipitated proteins were subjected to Western blot analysis using the same anti-HA antibody (numbers below the blots correspond to in-house
numbering of the mice); IgGH band corresponds to the heavy chain of the immunoprecipitating IgG. (C) Immunohistochemistry for TRPC3-HA in aortic root
sections from endothelial-specific TRPC3-HA transgenic mice (“TgEST3”) or their nontransgenic littermates (“non-transgenic”). The fuchsia-colored deposit on
the endothelium in the TgEST3 section denotes positive immunoreactivity for the HA epitope. Background staining in sections from nontransgenic mice was
not different from the negative control. L, arterial lumen.
Table 1. Body weight and lipid profile for ApoeKO and
TgEST3ApoeKO mice
Parameter ApoeKO TgEST3ApoeKO
Total cholesterol (mg/dL) 1,138 ± 105 1,016 ± 55
1,040 ± 55 1,103 ± 105
Triglycerides (mg/dL) 329 ± 64 322 ± 31
229 ± 39 220 ± 40
Body weight after diet (g) 29.1 ± 2.16 26.6 ± 1.3
28.6 ± 1.10 29.7 ± 1.3
Mice were fed a HFD for 10 (first row of values for each parameter) and
16 wk (second row of values for each parameter), and body weight and total
plasma cholesterol and triglycerides were measured as described in Meth-
ods. Values are mean ± SEM, n = 10 for all parameters. All P values were
>0.05 (not statistically significant) according to the Mann–Whitney u test.
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(n = 10), for TgEST3ApoeKO vs. ApoeKO, respectively; P =
0.094]. Neutral lipid content, as assessed by Oil Red O (ORO)
staining, was not different [267,823 ± 38,379 μm2 (n = 10) vs.
256,274 ± 39,266 μm2 (n = 10), for TgEST3ApoeKO vs. ApoeKO,
respectively; P = 0.57]. At this stage, lesion macrophage content
was similar between the two groups [MOMA2-positive area:
285,357 ± 66,471 μm2 (n = 10) vs. 258,782 ± 41,833 μm2 (n = 10),
for TgEST3ApoeKO vs. ApoeKO, respectively; P = 0.80]. At this
time point, areas of necrosis were not evident in lesions examined
throughout the entire aortic root.
We next examined the aortic root lesions in mice maintained on
HFD for 16 wk. As expected, plaques at this stage were larger than
those observed after 10 wk on HFD (P = 0.002), and areas of
necrosis were clearly identifiable. As shown in Fig. 2, morpho-
metric analysis of H&E stained plaques showed a marked increase
in total lesion area in TgEST3ApoeKO mice compared with
control animals [574,407 ± 55,416 μm2 (n = 9) vs. 372,724 ±
62,787 μm2 (n = 9), respectively; P = 0.019]. A similar result was
obtained when analyzing ORO stained-sections, which were larger
in the transgenic animals [355,614 ± 23,520 μm2 (n = 10) vs.
224,993 ± 36,398 μm2 (n = 10), for TgEST3ApoeKO vs. ApoeKO,
respectively; P = 0.026, Fig. 2]. Notably, the macrophage content
of these plaques was markedly augmented compared with the
nontransgenic littermates [MOMA2-positive area: 524,606 ±
29,766 μm2 (n = 6) vs. 263,469 ± 76,483 μm2 (n = 6), for TgES-
T3ApoeKO vs. nontransgenic littermates, respectively; P = 0.015,
Fig. 3]. The significant overlap between ORO and MOMA2
positive areas suggests that lesional lipid is contained, to a great
extent, in macrophages. In those lesions where necrosis was pre-
sent, the areas of necrosis were, on average, significantly larger in
the transgenic mice compared with those in the nontransgenic
littermates [32,703 ± 3,956 μm2 (n = 6) vs. 16,134 ± 3,362 μm2
(n = 8), for TgEST3ApoeKO vs. ApoeKO, respectively; P =
0.019]. In advanced atherosclerotic plaques, macrophage apopto-
sis plays a key role in formation and growth of areas of necrosis
(11, 16). Using a modified in situ TUNEL technique we examined
if endothelial overexpression of hTRPC3 affected accumulation of
apoptotic cells in mice maintained on HFD for 16 wk. Whereas
apoptotic (TUNEL+) cells were clearly evident in lesions from
both groups of animals, the total number of apoptotic cells was
similar [24.1 ± 5.8 cells per mm2 (n = 8) vs. 13.5 ± 2.0 cells per
mm2 (n = 8), for TgEST3ApoeKO vs. ApoeKO, respectively; P =
0.094]. To determine whether differences in macrophage content
between lesions of TgEST3ApoeKO and nontransgenic litter-
mates was related to differences in the extent of proliferation of
lesional macrophages, aortic root sections from animals fed HFD
for 16 wk were subjected to immunostaining for the nuclear an-
tigen Ki67, a marker of cell proliferation. Evidence of actively
proliferating cells was barely detectable and there were no differ-
ences between TgEST3ApoeKO and ApoeKO mice (1.1 ± 0.9 vs.
2.0 ± 0.8 Ki67+ cells per mm2, for TgEST3ApoeKO vs. ApoeKO,
respectively; n = 8 for both groups, P = 0.42).
In previous in vitro studies using human coronary artery en-
dothelial cells we found that increased expression of TRPC3
resulting from either exposing cells to proatherogenic stimuli or
by overexpressing TRPC3-HA, resulted in higher expression
levels of VCAM-1 in a NFkB dependent manner (12, 13). To
determine whether, in vivo and in the setting of atherosclerosis,
endothelial overexpression of hTRPC3 affected lesional ex-
pression of VCAM-1, we performed immunofluorescence on
aortic root sections from TgEST3ApoeKO mice and their non-
transgenic littermates to evaluate VCAM-1 immunoreactivity
and its distribution along the endothelial lining. Representative
stained sections are shown in Fig. 4. In vivo, endothelial VCAM-1
immunoreactivity can appear patchy and/or evenly distributed,
and is not restricted to endothelium but it is also evident in other
lesional cells (17, 18). Four independent operators blind to the
study group scored the VCAM-1 staining that localized to en-
dothelium as of low, intermediate, or high intensity, and as of
having diffuse or even distribution along the endothelial lining.
After analyzing the categorical scores in contingency tables,
lesions from TgEST3ApoeKO mice maintained on HFD for
10 wk exhibited a more robust staining for VCAM-1, mostly at
the expense of an increase in the number of sections showing
staining with intermediate intensity of immunoreactivity (48% vs.















Fig. 2. Lesion area and lipid content. Aortic root sections from TgEST3A-
poeKO mice or their transgenic littermates (ApoeKO) that were maintained
on a 16 wk high fat diet, were stained with hematoxylin-eosin (H&E) or Oil-
Red-O (ORO) to evaluate lesion area and neutral lipid content, respectively.




Fig. 3. Macrophage/monocyte content. Atherosclerotic lesions in aortic
root sections from TgEST3ApoeKO mice or their transgenic littermates
(ApoeKO) that were maintained on a 16 wk high fat diet, were stained with
MOMA-2 antibody to evaluate macrophage content. Shown are represen-
tative sections and corresponding quantitations of the stained areas for each
group of animals. P values were determined using the Mann–Whitney u test.

















χ2 test). However, at this time point, there were no significant
differences in the distribution of VCAM-1 along the endothelial
lining. The above difference in VCAM-1 immunoreactivity was
also noted in lesions from mice maintained for 16 wk on HFD,
although in this case it did not reach statistical significance (57%
vs. 42%, for TgEST3ApoeKO vs. ApoeKO, respectively; P =
0.09, χ2 test). Notably, the distribution pattern of VCAM-1
staining in lesions from mice on 16-wk HFD was clearly shifted
toward an increase in the presence of patches of VCAM-1 ex-
pression (82% vs. 58%, for TgEST3ApoeKO vs. ApoeKO, re-
spectively; P = 0.0003, Fisher’s exact test; Fig. 4). Interestingly,
immunostaining for phospho-IkBα, an indirect indication of
NFkB activation, was evidently more robust and noticeable along
the endothelial lining of sections from TgEST3ApoeKO mice
than those from controls after both 10 and 16 wk on HFD
(Fig. 5).
Discussion
A number of previous studies from other groups, although not
directly aimed at studying atherosclerosis, provided evidence
somewhat supportive of the notion of a potential relationship be-
tween expression and/or function of members of the TRPC family
of cation channels in the endothelium and events associated to the
pathogenesis of atherosclerosis (reviewed by us in ref. 2). For in-
stance, it is well established that TRPC3 participates in oxidative
stress signaling, a recognized factor in vascular inflammation (19,
20). In bovine aortic endothelial cells migration is inhibited by
lysophosphatidylcholine, a major component of oxidized low den-
sity lipoprotein, through a mechanism that requires sustained cal-
cium influx mediated by the sequential activation of TRPC6 and
TRPC5 (21). TRPC6 is also required for the angiogenic actions of
vascular endothelial growth factor in endothelial cells (22, 23)
suggesting a role of this TRPC in neoangiogenesis, a process often
observed in advanced atherosclerotic plaques. Our previous in vitro
studies showing that TRPC3 is an obligatory component of the
mechanism driving expression of VCAM-1 and monocyte adhesion
in human coronary artery endothelial cells, and that expression
of native endothelial TRPC3 is up-regulated by proatherogenic
factors, was to our knowledge the first direct evidence linking
expression/function of endothelial TRPC3 to molecular and
cellular events of relevance to atherosclerosis (12, 13). In addi-
tion, we reported that murine atherosclerotic lesions exhibit
robust expression of TRPC3 compared with arterial cross-sec-
tions from nonatherosclerotic animals (13). Despite these find-
ings, the multifactorial nature of lesion development in vivo
impeded for any definitive association to be made between en-
dothelial TRPC3 and atherogenesis. Hence, the necessity of
generating a mouse model of atherosclerosis in which TRPC3
expression could be manipulated (i.e., conditional transgenic or
knockout animals for TRPC3) was obvious. In the present
studies, we introduced a unique mouse model of atherosclerosis
with endothelial-specific overexpression of human TRPC3 to
examine the impact of endothelial overexpression of this channel
on the characteristics of atherosclerotic lesions.
Our findings show that whereas lesion size and macrophage
content of early stage lesions in TgEST3ApoeKO were not dif-
ferent from those in nontransgenic littermates, advanced plaques
were significantly larger and with markedly increased cellularity
in the transgenic mice compared with control animals. In pre-
vious work we demonstrated that the immediate consequence
of the augmented expression of TRPC3 that follows exposure of
endothelial cells to proatherogenic factors, is a higher number
of plasma membrane resident TRPC3 channels operating in
constitutive mode, and this in turn enhanced NFkB-dependent
expression of VCAM-1 and monocyte adhesion (12, 13). The
present findings show that in advanced lesions from TgEST3A-
poeKO mice the presence of patches of VCAM-1 expression
along the endothelial lining was greater than in lesions from
nontransgenic littermates, with the increased immunoreac-
tivity for VCAM-1 being already evident after 10 wk on high
fat diet. Interestingly, the appearance of endothelial patches of
VCAM-1 expression in vivo has been correlated to clusters of
newly expressed molecules (24–26). Remarkably, compared with
control animals the extent of NFkB activation in endothelium
from TgEST3ApoeKO, as evidenced by the extent of phospho-
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Fig. 4. VCAM-1 expression. Aortic root sections from TgEST3ApoeKO mice
or their transgenic littermates (ApoeKO) that were maintained on a 10 or
16 wk high fat diet regimen were stained for VCAM-1 (red) and DAPI (nu-
clei). In the negative control, VCAM-1 antibody was replaced by an equiva-
lent dilution of normal rat serum (see Methods for details). Typical
immunoreactive areas (white dotted box in full image) are shown enlarged
in the insets. The VCAM-1 staining that localized to endothelium was scored
by four independent operators blind to the study groups, as of low, in-
termediate or high intensity, and as of having patchy or even distribution
along the endothelial lining. The categorical scores were analyzed in con-

















Fig. 5. NFkB activation. Aortic root sections from TgEST3ApoeKO mice or
their transgenic littermates (ApoeKO) that were maintained on a 10 or
16 wk high fat diet regimen were stained for phospho-IkBα (red) and DAPI
(nuclei). The negative control was processed as indicated in Methods,
replacing the primary anti-phospho-IkBα antibody by an equivalent dilution
of normal goat serum. Typical immunoreactive areas (white dotted box in
full image) are shown enlarged in the insets.
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observations in a mouse model of atherosclerosis revisited the
mechanism of macrophage accumulation during lesion develop-
ment, suggesting that as lesion progresses proliferation of lesional
macrophages, rather than continuous monocyte influx, accounts for
a significant proportion of the macrophage content in the lesion
(27). When examining immunoreactivity for the nuclear antigen
Ki67 in advanced aortic root lesions from both TgEST3ApoeKO
and nontransgenic mice we did not find differences in the number
of proliferating lesional cells, indicating that the marked increase in
plaque cellularity exhibited by the TgEST3ApoeKO animals can-
not be attributed to changes in macrophage proliferation. Alto-
gether, our results suggest that the increased cellularity of lesions
from TgEST3ApoeKO mice is likely due, at least in part, to aug-
mented monocyte recruitment that follows increased endothelial
inflammatory signaling and VCAM-1 expression. It is reasonable
to speculate that, similar to what we observed in human coronary
artery endothelial cells (12, 13), much of the impact of endothelial
overexpression of TRPC3 on VCAM-1 expression and the in-
flammatory status of the endothelium of TgEST3ApoeKO mice is
presumably subsequent to increased TRPC3-mediated constitutive
calcium influx into the endothelial cells. This adds to previous ex-
amples of the biological consequences of a gain in TRPC3 con-
stitutive function. Indeed, mice with global deficiency of TRPC6
exhibit compensatory up-regulated expression of TRPC3 which
results in elevated vessel tone in both aorta and cerebral arteries
mostly due to augmented constitutive calcium influx (28). In
mouse skeletal myocytes increased TRPC3 expression and the
gain in constitutive calcium entry correlates with enhanced basal
NFAT activity (29). In this context, the present findings can be
taken as, to our knowledge, the first in vivo evidence illustrating
the impact of augmented expression of endothelial TRPC3 on
atherosclerosis, and support our previous postulate that up-regu-
lated expression of a calcium-permeable channel endowed with
significant constitutive function may have pathological relevance
(13). However, a contribution also from regulated TRPC3 activity
cannot be ruled out here, because of the existence of a myriad of
circulating factors that can, in vivo, further increase channel ac-
tivity. Remarkably, and regardless of the extent of contribution of
constitutive vs. regulated TRPC3 function in vivo, the positive
correlation observed between larger plaque burden, cellularity,
VCAM-1 expression and NFkB activation in the TgEST3ApoeKO
mice are in line with our previous in vitro findings (13) and vali-
date our prediction that in vivo and in the setting of atheroscle-
rosis, endothelial TRPC3 supports inflammatory signaling and
contributes to lesion cellularity (13).
Interestingly, the lipid content of advanced lesions was greater
in TgEST3ApoeKO mice compared with their nontransgenic lit-
termates. Although a definitive assignment of lipid location to a
particular cell type cannot be made based solely on histological
evaluation, the significant overlap between ORO and MOMA2
positive areas indicates that the majority of lesional lipid is con-
tained in macrophages. Because plasma lipids are similar between
TgEST3ApoeKO and nontransgenic mice, this observation sug-
gests that augmented endothelial expression of TRPC3 somehow
influences lipid accumulation in the plaque, possibly by promoting
alterations in endothelial lipid transport and/or in the production
of endothelial-derived cytokines that, directly or indirectly, may
influence the lipid handling capability of lesional macrophages.
Accumulation of apoptotic macrophages in advanced athero-
sclerotic lesions is mostly due to impairment of the efferocytic
functions of resident phagocytes as the lesion progresses and
contributes to formation of necrotic cores (30). Interestingly,
whereas the density of apoptotic macrophages was similar in ad-
vanced lesions from TgEST3ApoeKO mice compared with those
from controls, the areas of necrosis were larger in the transgenic
mice. Whether an association exists between expression/function
of endothelial TRPC3 and the development of lesional necrosis,
one that could be related to endothelial-derived factors directly or
indirectly affecting the composition of the necrotic core, warrants
further investigation.
Despite compelling evidence accumulated over the last two
decades documenting the participation of TRPCs in mechanisms
associated to the pathogenesis of cardiovascular diseases (reviewed
by us in (1, 2)), the role of these channels forming proteins in
atherosclerosis has remained largely unexplored. Our recent
studies showing that bone marrow deficiency of TRPC3 reduces
macrophage apoptosis and necrosis of advanced plaques in a
mouse model of the disease (11) constitute, to our knowledge, the
first available experimental in vivo evidence supporting a role of
TRPC3 in murine atherosclerosis. In a more recent study, we
found that the impact of TRPC3 deficiency on macrophage apo-
ptosis is due to its supportive role in mechanisms that drive en-
doplasmic reticulum stress-induced apoptosis of M1 macrophages
(15). We now show that, as predicted in previous in vitro studies in
coronary artery endothelial cells (12, 13), augmented expression of
endothelial TRPC3 also has profound effects in the characteristics
of advanced atherosclerotic lesions. Taken together, our previous
and present observations suggest that in the setting of athero-
sclerosis TRPC3 has distinctive proatherogenic effects by virtue of
its unique functions in two atherorelevant cell types.
Interestingly, analysis of expression profile studies using human
genomic microarrays shows significant up-regulation of TRPC3
mRNA levels in plaques derived from patients with atheroscle-
rotic lesions in the left anterior descendent coronary artery (31).
In circulating monocytes from three out of four patients homo-
zygous for familial hypercholesterolemia, the TRPC3 mRNA was
notoriously up-regulated compared with heterozygous or control
patients (32). Despite these suggestive data showing a correlation
between increased expression levels of TRPC3 and presence of
atherosclerosis, whether TRPC3 has an active role in the patho-
genesis of the human lesion, remains unknown. In that context,
the present and our previous work provide a platform to start
defining, by analogy to the roles of TRPC3 in murine lesions,
cellular and molecular correlates in the human pathology that
might be influenced by TRPC3 expression and/or function.
Methods
Aortic root sectioning, morphometric analysis of atherosclerotic lesions, and
immunohistochemistry and immunofluorescence evaluation of lesion com-
position was performed essentially as we described in refs. 11 and 13. Ad-
ditional details on protocols and source of antibodies are provided below.
Experimental Animals and Generation of Endothelial TRPC3 Transgenic Mice. All
studies involving animals described in this work conform to the Guide for the
Care and Use of Laboratory Animals published by the US National Institutes of
Health and have been approved by University of Toledo IACUC. C57BL/6 mice
and the ApoeKO (B6.129P2-Apoetm1Unc/J) mice were obtained from Jackson
Labs, and colonies were maintained in our animal facility. Euthanasia was per-
formed by i.p. injection of sodium pentobarbital (150 mg/kg, plus 10 Units/mL
of heparin). Mice with endothelial-specific overexpression of human TRPC3
(hTRPC3) were generated by using the human Flt-1 promoter (InVivoGen) to
drive endothelial expression of wild-type human TRPC3. TRPC3 cDNA with
C-terminal hemagglutinin (HA) epitope (33) was cloned into pDRIVE (InVivoGen)
between the Flt-1 promoter and the SV40 polyA. Human and mouse TRPC3 are
more than 93% identical at the gene and protein level and indistinguishable in
terms of functional and pharmacological properties (5). TRPC3-HA has been
shown to be functional in mice with cardiomyocyte overexpression of TRPC3HA
(34) and in several cell types in vitro (5, 33, 35). The Flt-1/TRPC3-HA minigene
(5,178 bp) was sequenced, excised, purified, and injected into C57BL/6
oocytes (Diabetes and Endocrinology Research Molecular Core, Yale School
of Medicine, New Haven, CT). PCR of tail gDNA from founders (primers TgF:
5′-AAGACAAGAGCCAAGCAACTGA; TgR: 5′-CTCCCCCTGAACCTGAAACA) ren-
dered the expected 334 bp amplicon corresponding to the last 92 bp of
Trpc3+HA+212 bp of the polyA. Founders with the endothelium-specific
TRPC3 transgene (TgEST3 - F0, 2 males, 3 females) represented fully inbred
F0 lines on C57BL/6 background. Once transferred to our facility F0 mice were
mated with C57BL/6 breeders; all were fertile and passed the transgene
to progeny with no gross phenotypes being observed. At F4 high and
low expressors were identified by Western blot analysis of TRPC3-HA in lung

















lysates and these lines were maintained on C57BL/6 background; high
expressor lines were intercrossed with ApoEKO mice (C57BL/6 background)
to generate TgEST3ApoEKO mice (see Fig. 1A; genotyping for ApoE allele
was performed according to Jackson Labs recommendations).
Determination of Plasma Cholesterol and Triglycerides. After a 12-h fasting
period blood was collected by submandibular vein puncture. Total plasma cho-
lesterol and triglyceride concentrations were determined using Cholesterol-E and
L-Type Triglyceride-M (Wako Chemicals) following manufacturer’s instructions.
Aortic Root Sectioning. Aortic root sections were prepared as we described in
refs. 11 and 13. Briefly, euthanized mice were perfused through the left
ventricle with 4% (wt/vol) paraformaldehyde followed by PBS. The heart
was cut so that all three aortic valves were in the same geometric plane, and
the upper portion was embedded in O.C.T., frozen in the Peltier stage of the
cryostat (Thermo Scientific R. Allan HM550 Cryostat) and sectioned. Sections
(10 μm) were collected onto Fisher Superfrost Plus-coated slides, starting
from where aorta exits the ventricle and moving toward the aortic sinus
(∼650–700 μm). Lesion analysis, Oil Red O (ORO), hematoxylin and eosin
(H&E) and trichrome staining, as well as evaluation of necrotic cores and in
situ TUNEL (in situ cell death detection kit, Roche) were as described (11).
Immunohistochemistry. Immunohistochemistry was essentially as we described
in detail in refs. 11 and 13. Briefly, sections were fixed in acetone and processed
for immunostaining for MOMA-2 (Santa Cruz Biotechnology, catalog no.
sc-59332) followed by incubation with biotinylated rabbit anti-rat antibody
(Dako). After treatment with secondary antibodies sections were incubated
with alkaline phosphatase-conjugated streptavidin (Dako). Counterstaining
was with hematoxylin. Negative controls were performed by substituting the
primary antibody with nonimmune IgG from the same species and at the same
concentration. Under these conditions, nonspecific immunostaining was min-
imal or not detected. Stained areas were captured (Micropublisher 3.3 Mega-
pixel Cooled CCD Color Digital Camera) and measured (NIS Elements D).
Immunofluorescence for VCAM-1 and Phospho-IkBα. Sections were fixed in ice-
cold acetone (15 min) and treated with 0.1% hydrogen peroxide in TBS (15 min).
After blocking nonspecific binding sites with 3%BSA (1 h) sectionswere incubated
with anti-VCAM-1 antibody (1:100; Southern Biotech, catalog no. #1510-01)
overnight at 4 °C. Following washes in PBS, sections were incubated with anti-rat
Alexa-fluor 555 (Cell Signaling, catalog no. 4417; 1:2,000, 1 h), washed, and
mounted with Prolong Gold Antifade Reagent containing DAPI (Cell Signaling,
catalog no. 8961). For phospho-IkBα immunostaining, acetone-fixed sections were
soaked in PBS containing 1% Triton X-100 for 30 min (room temperature) and
blocked in 5% normal goat serum in PBS (30 min) before overnight incubation
(4 °C) in unconjugated AffiniPure Fab Fragment Goat Anti-Mouse IgG (H +L)
(1:10; Jackson ImmunoResearch Laboratories). Sections were washed in 0.1% PBS-
Tween-20 (30 min) and incubated with anti-phospho-IkBα antibody (Cell Signal-
ing, catalog no. 9246) for 1 h (room temperature), followed by an additional 1 h
incubation with anti-mouse Alexa-fluor 555 (Cell Signaling, catalog no. 4409).
After washing in 0.1% PBS-Tween-20 (30 min) slides were mounted with Prolong
Gold Antifade Reagent containing DAPI (Cell Signaling, catalog no. 8961). A
similar treatment was performed on sections processed for immunohistochemistry
using an anti-HA mouse monoclonal antibody (12CA5, as in ref. 33) followed by
incubation with biotinylated goat anti-mouse and alkaline phosphatase-conju-
gated streptavidin (Dako). Counterstaining was with hematoxylin.
Statistical Analysis. Values are shown as mean ± SEM. Comparisons between
groups was performed by Mann–Whitney u test using GraphPad Prism ver-
sion 6 for Windows 2007. P values below 0.05 were considered significant.
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